ANI Pharmaceuticals, Inc. (ANIP)

NASDAQ: ANIP · IEX Real-Time Price · USD
39.50
-0.09 (-0.23%)
Dec 9, 2022 4:00 PM EST - Market closed
-0.23%
Market Cap 691.00M
Revenue (ttm) 283.08M
Net Income (ttm) -69.20M
Shares Out 16.30M
EPS (ttm) -4.66
PE Ratio n/a
Forward PE 11.66
Dividend n/a
Ex-Dividend Date n/a
Volume 55,539
Open 39.57
Previous Close 39.59
Day's Range 38.13 - 39.9
52-Week Range 22.31 - 51.69
Beta 1.05
Analysts Buy
Price Target 44.12 (+11.7%)
Earnings Date Nov 9, 2022

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through ret... [Read more]

Industry Pharmaceuticals
Founded 2001
CEO Patrick Walsh
Employees 601
Stock Exchange NASDAQ
Ticker Symbol ANIP
Full Company Profile

Financial Performance

In 2021, ANIP's revenue was $216.14 million, an increase of 3.67% compared to the previous year's $208.48 million. Losses were -$42.60 million, 88.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is 44.12, which is an increase of 11.70% from the latest price.

Price Target
$44.12
(11.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

BAUDETTE, Minn.--( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the A...

1 week ago - Business Wire

ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP

BAUDETTE, Minn.--( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated Ne...

3 weeks ago - Business Wire

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective...

2 months ago - Business Wire

ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

3 months ago - Business Wire

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg. ANI's Prochlorpera...

3 months ago - Business Wire

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbrevi...

3 months ago - Business Wire

ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022...

4 months ago - Business Wire

Should You Buy ANI Pharmaceuticals (ANIP) Ahead of Earnings?

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules. ANI's Acebutolol Hydrochloride Capsul...

4 months ago - Business Wire

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a ...

4 months ago - Business Wire

ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on Monday, Aug...

4 months ago - Business Wire

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretar...

4 months ago - Business Wire

ANI (ANIP) Soars 6.2%: Is Further Upside Left in the Stock?

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5 months ago - Zacks Investment Research

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbrevi...

5 months ago - Business Wire

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

Partnership drives commercial excellence through precision engagement to benefit patients in need of options BAUDETTE, Minn. and PLEASANTON, Calif.

Other symbols: VEEV
5 months ago - PRNewsWire

ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium A...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant b...

6 months ago - Business Wire

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the A...

6 months ago - Business Wire

ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, ...

6 months ago - Business Wire

ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Fu...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended March 31, 2022. “Duri...

6 months ago - Business Wire